candesartan has been researched along with Myocardial Ischemia in 19 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Myocardial Ischemia: A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this study was to test the hypothesis that there are blood pressure independent CVD-risk differences between losartan and candesartan treatment in patients with hypertension without known CVD." | 7.76 | Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. ( Bodegard, J; Hasvold, P; Kjeldsen, SE; Olsson, U; Russell, D; Stålhammar, J, 2010) |
| "Pretreatment with imidapril (ACE inhibitor) and candesartan cilexitil (AT1 receptor antagonist) significantly prevented the increase in the phosphorylation of JAK1 at 120 min and STAT3 at 30 and 120 min." | 5.31 | Myocardial ischemia activates the JAK-STAT pathway through angiotensin II signaling in in vivo myocardium of rats. ( Beppu, S; Ishikura, F; Kobayashi, H; Omura, T; Takeuchi, K; Yoshikawa, J; Yoshiyama, M, 2001) |
| " The aim of this study was to test the hypothesis that there are blood pressure independent CVD-risk differences between losartan and candesartan treatment in patients with hypertension without known CVD." | 3.76 | Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. ( Bodegard, J; Hasvold, P; Kjeldsen, SE; Olsson, U; Russell, D; Stålhammar, J, 2010) |
| "The calcium antagonist felodipine, the lipid-peroxidation inhibitor H290/51, and the angiotensin II type 1 (AT1)-receptor antagonist candesartan all exert beneficial effects on myocardial ischemia/reperfusion injury." | 3.70 | Combination of a calcium antagonist, a lipid-peroxidation inhibitor, and an angiotensin AT1-receptor antagonist provides additive myocardial infarct size-limiting effect in pigs. ( Rydén, L; Shimizu, M; Sjöquist, PO; Wang, QD, 1999) |
| "Cardiac complications were defined as left ventricular hypertrophy (LVH) and ischemic heart disease (IHD)." | 1.35 | Effects of cardiac complications on cardiovascular events in Japanese high-risk hypertensive patients: subanalysis of the CASE-J trial. ( Fujimoto, A; Nakao, K; Oba, K; Ogihara, T; Saruta, T; Ueshima, K; Yasuno, S, 2009) |
| " The authors established with an initial dose-response curve using escalating concentrations of CN that 10 nmol/L abrogated vasoconstriction induced by angiotensin II (0." | 1.31 | Increased AT2R protein expression but not increased apoptosis during cardioprotection induced by AT1R blockade. ( Jugdutt, BI; Kumar, D; Moudgil, R; Musat-Marcu, S; Xu, Y, 2002) |
| "Pretreatment with imidapril (ACE inhibitor) and candesartan cilexitil (AT1 receptor antagonist) significantly prevented the increase in the phosphorylation of JAK1 at 120 min and STAT3 at 30 and 120 min." | 1.31 | Myocardial ischemia activates the JAK-STAT pathway through angiotensin II signaling in in vivo myocardium of rats. ( Beppu, S; Ishikura, F; Kobayashi, H; Omura, T; Takeuchi, K; Yoshikawa, J; Yoshiyama, M, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (21.05) | 18.2507 |
| 2000's | 11 (57.89) | 29.6817 |
| 2010's | 4 (21.05) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sakamoto, T | 1 |
| Ogawa, H | 1 |
| Nakao, K | 3 |
| Koide, S | 1 |
| Yamamoto, N | 1 |
| Shimomura, H | 1 |
| Matsumura, T | 1 |
| Oshima, S | 1 |
| Kikuta, K | 1 |
| Oka, H | 1 |
| Kimura, K | 1 |
| Matsui, K | 1 |
| Ueshima, K | 2 |
| Yasuno, S | 2 |
| Oba, K | 2 |
| Fujimoto, A | 2 |
| Ogihara, T | 2 |
| Saruta, T | 2 |
| Kjeldsen, SE | 1 |
| Stålhammar, J | 1 |
| Hasvold, P | 1 |
| Bodegard, J | 1 |
| Olsson, U | 1 |
| Russell, D | 1 |
| Tanaka, S | 1 |
| Fukumoto, T | 1 |
| Tawa, M | 1 |
| Kitada, K | 1 |
| Yamashita, N | 1 |
| Ohkita, M | 1 |
| Okamura, T | 1 |
| Matsumura, Y | 1 |
| Moudgil, R | 2 |
| Musat-Marcu, S | 1 |
| Xu, Y | 2 |
| Kumar, D | 1 |
| Jugdutt, BI | 2 |
| Richardt, D | 1 |
| Wolfrum, S | 1 |
| Büttner, C | 1 |
| Schäfer, U | 1 |
| Dendorfer, A | 1 |
| Kurz, T | 1 |
| Richardt, G | 1 |
| Higashikuni, Y | 1 |
| Sata, M | 1 |
| Nagai, R | 1 |
| Shimizu, M | 2 |
| Sjöquist, PO | 2 |
| Wang, QD | 2 |
| Rydén, L | 2 |
| Matoba, S | 1 |
| Tatsumi, T | 1 |
| Keira, N | 1 |
| Kawahara, A | 1 |
| Akashi, K | 1 |
| Kobara, M | 1 |
| Asayama, J | 1 |
| Nakagawa, M | 1 |
| Sharma, A | 1 |
| Singh, M | 1 |
| Kawabata, H | 4 |
| Ryomoto, T | 3 |
| Ishikawa, K | 4 |
| Balghith, M | 1 |
| Menon, V | 1 |
| Omura, T | 1 |
| Yoshiyama, M | 1 |
| Ishikura, F | 1 |
| Kobayashi, H | 1 |
| Takeuchi, K | 1 |
| Beppu, S | 1 |
| Yoshikawa, J | 1 |
| Hiura, N | 1 |
| Wakatsuki, T | 1 |
| Yamamoto, T | 1 |
| Nishikado, A | 1 |
| Oki, T | 1 |
| Ito, S | 1 |
| Nakagawa, K | 1 |
1 trial available for candesartan and Myocardial Ischemia
| Article | Year |
|---|---|
Rationale, design and baseline characteristics of a study to evaluate effects of candesartan on cardiovascular events after drug-eluting stent implantation in patients with ischemic heart disease.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Angiotensin II Type 1 Receptor Blockers; Be | 2013 |
18 other studies available for candesartan and Myocardial Ischemia
| Article | Year |
|---|---|
Effects of cardiac complications on cardiovascular events in Japanese high-risk hypertensive patients: subanalysis of the CASE-J trial.
Topics: Adrenergic Antagonists; Aged; Amlodipine; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Calciu | 2009 |
Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; F | 2010 |
Influence of coronary risk factors on coronary events in Japanese high-risk hypertensive patients. - Primary and secondary prevention of ischemic heart disease in a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) tria
Topics: Aged; Amlodipine; Antihypertensive Agents; Asian People; Benzimidazoles; Biphenyl Compounds; Coronar | 2011 |
Different effects of AT1 receptor antagonist and ET(A) receptor antagonist on ischemia-induced norepinephrine release in rat hearts.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atrasentan; Benzimidazoles; Biphenyl Compounds; Di | 2012 |
Increased AT2R protein expression but not increased apoptosis during cardioprotection induced by AT1R blockade.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Apoptosis; Benzimidazoles; Biphe | 2002 |
Effect of ACE-inhibitor ramiprilat and AT1-receptor antagonist candesartan on cardiac norepinephrine release: comparison between ischemic and nonischemic conditions.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; | 2002 |
Reversible left ventricular hypertrophy after tako-tsubo-like cardiomyopathy.
Topics: Aged; Aspirin; Benzimidazoles; Biphenyl Compounds; Cardiomyopathy, Dilated; Chest Pain; Drug Therapy | 2005 |
Effects of the angiotensin AT1 receptor blocker candesartan on myocardial ischemic/reperfusion injury.
Topics: Angiotensin Receptor Antagonists; Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; Calcium | 1999 |
Cardioprotective effect of angiotensin-converting enzyme inhibition against hypoxia/reoxygenation injury in cultured rat cardiac myocytes.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti | 1999 |
Role of angiotensin in cardioprotective effect of ischemic preconditioning.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Coron | 1999 |
Combination of a calcium antagonist, a lipid-peroxidation inhibitor, and an angiotensin AT1-receptor antagonist provides additive myocardial infarct size-limiting effect in pigs.
Topics: Anesthesia; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Antioxidants; Benzim | 1999 |
Effect of angiotensin converting enzyme inhibitor and angiotensin II type 1 receptor antagonist on metabolism and contraction in ischemia-reperfused rabbit heart.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2000 |
Cardioprotection induced by AT1R blockade after reperfused myocardial infarction: association with regional increase in AT2R, IP3R and PKCepsilon proteins and cGMP.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Calcium Channels; Cyc | 2000 |
Myocardial ischemia activates the JAK-STAT pathway through angiotensin II signaling in in vivo myocardium of rats.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blotting, West | 2001 |
Role of cardiac ATP-sensitive K+ channels induced by angiotensin II type 1 receptor antagonist on metabolism, contraction and relaxation in ischemia-reperfused rabbit heart.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 2001 |
Cardioprotection with angiotensin converting enzyme inhibitor and angiotensin II type 1 receptor antagonist is not abolished by nitric oxide synthase inhibitor in ischemia-reperfused rabbit hearts.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; | 2001 |
Effects of angiotensin II type 1 receptor antagonist (candesartan) in preventing fatal ventricular arrhythmias in dogs during acute myocardial ischemia and reperfusion.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Dogs; Heart Conductio | 2001 |
Effects of an HMG-CoA reductase inhibitor in combination with an ACE inhibitor or angiotensin II type 1 receptor antagonist on myocardial metabolism in ischemic rabbit hearts.
Topics: Adenosine Triphosphate; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2002 |